WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced the initiation of a Phase 2 trial for its investigational drug bosakitug (ATI-045), targeting moderate-to-severe atopic dermatitis ...

The AAP defines proactive care as an “ evidence-based ” approach based on “intermittent use of anti-inflammatory agents (eg, ...